{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25070468",
  "DateCompleted": {
    "Year": "2015",
    "Month": "06",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s10803-014-2184-9"
    ],
    "Journal": {
      "ISSN": "1573-3432",
      "JournalIssue": {
        "Volume": "44",
        "Issue": "12",
        "PubDate": {
          "Year": "2014",
          "Month": "Dec"
        }
      },
      "Title": "Journal of autism and developmental disorders",
      "ISOAbbreviation": "J Autism Dev Disord"
    },
    "ArticleTitle": "A systematic review of treatments for anxiety in youth with autism spectrum disorders.",
    "Pagination": {
      "StartPage": "3215",
      "EndPage": "3229",
      "MedlinePgn": "3215-29"
    },
    "Abstract": {
      "AbstractText": [
        "This study systematically examined the efficacy and safety of psychopharmacological and non-psychopharmacological treatments for anxiety in youth with autism spectrum disorders (ASD). Four psychopharmacological, nine cognitive behavioral therapy (CBT), and two alternative treatment studies met inclusion criteria. Psychopharmacological studies were descriptive or open label, sometimes did not specify the anxiety phenotype, and reported behavioral activation. Citalopram and buspirone yielded some improvement, whereas fluvoxamine did not. Non-psychopharmacological studies were mainly randomized controlled trials (RCTs) with CBT demonstrating moderate efficacy for anxiety disorders in youth with high functioning ASD. Deep pressure and neurofeedback provided some benefit. All studies were short-term and included small sample sizes. Large scale and long term RCTs examining psychopharmacological and non-psychopharmacological treatments are sorely needed."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Kennedy Krieger Institute, 3901 Greenspring Avenue, Baltimore, MD, 21211, USA, vasa@kennedykrieger.org."
          }
        ],
        "LastName": "Vasa",
        "ForeName": "Roma A",
        "Initials": "RA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Carroll",
        "ForeName": "Laura M",
        "Initials": "LM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nozzolillo",
        "ForeName": "Alixandra A",
        "Initials": "AA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mahajan",
        "ForeName": "Rajneesh",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mazurek",
        "ForeName": "Micah O",
        "Initials": "MO"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bennett",
        "ForeName": "Amanda E",
        "Initials": "AE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wink",
        "ForeName": "Logan K",
        "Initials": "LK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bernal",
        "ForeName": "Maria Pilar",
        "Initials": "MP"
      }
    ],
    "GrantList": [
      {
        "GrantID": "UA3 MC 11054",
        "Agency": "PHS HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, U.S. Gov't, P.H.S.",
      "Review",
      "Systematic Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Autism Dev Disord",
    "NlmUniqueID": "7904301",
    "ISSNLinking": "0162-3257"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0DHU5B8D6V",
      "NameOfSubstance": "Citalopram"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [
        "epidemiology",
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [
        "epidemiology",
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Child Development Disorders, Pervasive"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Citalopram"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Cognitive Behavioral Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}